{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:27:16Z","timestamp":1788280036854,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62171299"],"award-info":[{"award-number":["62171299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2017YFC0907700"],"award-info":[{"award-number":["2017YFC0907700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00415-025-13367-8","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:37:04Z","timestamp":1757360224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study"],"prefix":"10.1007","volume":"272","author":[{"given":"Wenjia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-148X","authenticated-orcid":false,"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"3","key":"13367_CR1","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1212\/cpj.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y et al (2024) Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract 14(3):e200-276. https:\/\/doi.org\/10.1212\/cpj.0000000000200276","journal-title":"Neurol Clin Pract"},{"issue":"5","key":"13367_CR2","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T et al (2024) The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol 271(5):2298\u20132308. https:\/\/doi.org\/10.1007\/s00415-024-12247-x","journal-title":"J Neurol"},{"issue":"7","key":"13367_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS (2023) The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23(7):415\u2013432. https:\/\/doi.org\/10.1038\/s41577-022-00821-1","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"13367_CR4","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/jci97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128(10):4372\u20134386. https:\/\/doi.org\/10.1172\/jci97911","journal-title":"J Clin Invest"},{"issue":"7","key":"13367_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"6","key":"13367_CR6","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","volume":"271","author":"L Fuchs","year":"2024","unstructured":"Fuchs L, Shelly S, Vigiser I et al (2024) Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol 271(6):3462\u20133470. https:\/\/doi.org\/10.1007\/s00415-024-12293-5","journal-title":"J Neurol"},{"key":"13367_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-019-0023-3","volume":"1","author":"H Stetefeld","year":"2019","unstructured":"Stetefeld H, Schroeter M (2019) SOP myasthenic crisis. Neurol Res Pract 1:19. https:\/\/doi.org\/10.1186\/s42466-019-0023-3","journal-title":"Neurol Res Pract"},{"key":"13367_CR8","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"13367_CR9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W et al (2024) Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol 11(8):2212\u20132221. https:\/\/doi.org\/10.1002\/acn3.52142","journal-title":"Ann Clin Transl Neurol"},{"key":"13367_CR10","doi-asserted-by":"publisher","first-page":"1407418","DOI":"10.3389\/fneur.2024.1407418","volume":"15","author":"P Wang","year":"2024","unstructured":"Wang P, Zhang B, Yin J et al (2024) Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol 15:1407418. https:\/\/doi.org\/10.3389\/fneur.2024.1407418","journal-title":"Front Neurol"},{"key":"13367_CR11","doi-asserted-by":"publisher","first-page":"175628642413111","DOI":"10.1177\/17562864241311127","volume":"18","author":"G Zhu","year":"2025","unstructured":"Zhu G, Zhou H, Wang W et al (2025) Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study. Ther Adv Neurol Disord 18:17562864241311128. https:\/\/doi.org\/10.1177\/17562864241311127","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"13367_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mus.28184","volume":"70","author":"L Remijn-Nelissen","year":"2024","unstructured":"Remijn-Nelissen L, Tannemaat MR, Ruiter AM, Campman YJM, Verschuuren J (2024) Efgartigimod in refractory autoimmune myasthenia gravis. Muscle Nerve 70(3):325\u2013332. https:\/\/doi.org\/10.1002\/mus.28184","journal-title":"Muscle Nerve"},{"key":"13367_CR13","doi-asserted-by":"publisher","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Huan X et al (2024) Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol 15:1418503. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503","journal-title":"Front Immunol"},{"issue":"4","key":"13367_CR14","doi-asserted-by":"publisher","first-page":"e16189","DOI":"10.1111\/ene.16189","volume":"31","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F et al (2024) Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center. Eur J Neurol 31(4):e16189. https:\/\/doi.org\/10.1111\/ene.16189","journal-title":"Eur J Neurol"},{"issue":"5","key":"13367_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268. https:\/\/doi.org\/10.1038\/nrneurol.2016.44","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"13367_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S et al (2023) Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 94(6):467\u2013473. https:\/\/doi.org\/10.1136\/jnnp-2022-330519","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13367_CR17","doi-asserted-by":"publisher","first-page":"1259484","DOI":"10.3389\/fneur.2023.1259484","volume":"14","author":"L Zhen","year":"2023","unstructured":"Zhen L, Zhao X, Li W et al (2023) Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study. Front Neurol 14:1259484. https:\/\/doi.org\/10.3389\/fneur.2023.1259484","journal-title":"Front Neurol"},{"issue":"2","key":"13367_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s13311-022-01335-3","volume":"20","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S et al (2023) Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis. Neurotherapeutics 20(2):518\u2013523. https:\/\/doi.org\/10.1007\/s13311-022-01335-3","journal-title":"Neurotherapeutics"},{"issue":"11","key":"13367_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and safety of Rituximab for new-onset generalized Myasthenia Gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"issue":"9","key":"13367_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2019.07.006","volume":"29","author":"RHP de Meel","year":"2019","unstructured":"de Meel RHP, Tannemaat MR, Verschuuren J (2019) Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord 29(9):664\u2013670. https:\/\/doi.org\/10.1016\/j.nmd.2019.07.006","journal-title":"Neuromuscul Disord"},{"key":"13367_CR21","doi-asserted-by":"publisher","first-page":"594152","DOI":"10.3389\/fneur.2020.594152","volume":"11","author":"Z Fan","year":"2020","unstructured":"Fan Z, Li Z, Shen F et al (2020) Favorable effects of Tacrolimus monotherapy on Myasthenia Gravis patients. Front Neurol 11:594152. https:\/\/doi.org\/10.3389\/fneur.2020.594152","journal-title":"Front Neurol"},{"issue":"1","key":"13367_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0303-8467(03)00046-5","volume":"106","author":"N Wakata","year":"2003","unstructured":"Wakata N, Saito T, Tanaka S, Hirano T, Oka K (2003) Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 106(1):5\u20138. https:\/\/doi.org\/10.1016\/s0303-8467(03)00046-5","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"13367_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/nejm198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316(12):719\u2013724. https:\/\/doi.org\/10.1056\/nejm198703193161205","journal-title":"N Engl J Med"},{"key":"13367_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RS Tindall","year":"1993","unstructured":"Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K (1993) A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 681:539\u2013551. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb22937.x","journal-title":"Ann N Y Acad Sci"},{"key":"13367_CR25","doi-asserted-by":"publisher","first-page":"175628642513196","DOI":"10.1177\/17562864251319656","volume":"18","author":"L Jin","year":"2025","unstructured":"Jin L, Zou Z, Wang Q et al (2025) Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes. Ther Adv Neurol Disord 18:17562864251319656. https:\/\/doi.org\/10.1177\/17562864251319656","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"13367_CR26","doi-asserted-by":"publisher","first-page":"e16098","DOI":"10.1111\/ene.16098","volume":"31","author":"V Bril","year":"2024","unstructured":"Bril V, Howard JF Jr., Karam C et al (2024) Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. Eur J Neurol 31(1):e16098. https:\/\/doi.org\/10.1111\/ene.16098","journal-title":"Eur J Neurol"},{"issue":"1","key":"13367_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12883-025-04063-1","volume":"25","author":"F Shi","year":"2025","unstructured":"Shi F, Lai R, Feng L et al (2025) Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit. BMC Neurol 25(1):79. https:\/\/doi.org\/10.1186\/s12883-025-04063-1","journal-title":"BMC Neurol"},{"key":"13367_CR28","doi-asserted-by":"publisher","first-page":"114603","DOI":"10.1016\/j.intimp.2025.114603","volume":"154","author":"J Chen","year":"2025","unstructured":"Chen J, Zhu X, Zhou H et al (2025) Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: a comparative multi-center study. Int Immunopharmacol 154:114603. https:\/\/doi.org\/10.1016\/j.intimp.2025.114603","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13367-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13367-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13367-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:20:21Z","timestamp":1762147221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13367-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13367"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13367-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article note has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"622"}}